✦ LIBER ✦

Medroxyprogesterone acetate (MAP) plasma levels after simultaneous oral and intramuscular administration in cancer patients

✍ Scribed by Franco Pannuti; Carlo Maurizio Camaggi; Elena Strocchi; Michele Giovannini; Nadia Canova; Giovanna Murari

Publisher: Springer
Year: 1982
Tongue: English
Weight: 141 KB
Volume: 9
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00265393

No coin nor oath required. For personal study only.

✦ Synopsis

After simultaneous administration of medroxyprogesterone acetate (MAP) 1,000 mg PO and 1,000 mg IM to ten cancer patients, we observed mean plasma MAP profiles that could be exactly superimposed on the two absorption/decay curves obtained after administration of single doses IM or PO. Treatment with MAP given simultaneously by the IM and PO routes may be effective in overcoming the drawbacks of both routes, and can also more reliably guarantee plasma levels in the therapeutic range.

📜 SIMILAR VOLUMES

Medroxyprogesterone acetate (MAP) plasma

Medroxyprogesterone acetate (MAP) plasma levels after multiple high-dose administration in advanced cancer patients

✍ Carlo Maurizio Camaggi; Elena Strocchi; Michele Giovannini; Bruna Angelelli; Bar 📂 Article 📅 1983 🏛 Springer 🌐 English ⚖ 352 KB

Medroxyprogesterone acetate plasma levels were measured in advanced cancer patients after multiple PO or IM administration (500, 1000, 2000, 3000, 4000, and 5000 mg/day PO and 500, 1000, 2000 mg/day IM for 30 days). After PO administration, the plasma concentration rises quickly and plateau level is

Medroxyprogesterone acetate (MAP) and ta

Medroxyprogesterone acetate (MAP) and tamoxifen (TMX) plasma levels after simultaneous treatment with ‘low’ TMX and ‘high’ MAP doses

✍ Carlo M. Camaggi; Elena Strocchi; Nadia Canova; Barbara Costanti; Franco Pannuti 📂 Article 📅 1985 🏛 Springer 🌐 English ⚖ 270 KB

Plasma levels of medroxyprogesterone acetate (MAP), tamoxifen (TMX) and its major metabolites, 4-hydroxy TMX and desmethyl TMX, were determined in five patients with advanced breast cancer following simultaneous MAP (2,000 mg/day) and TMX (20 mg/day) oral therapy. The interindividual variance in MAP

Simultaneous determination of plasma hal

Simultaneous determination of plasma haloperidol and its metabolite reduced haloperidol by liquid chromatography with electrochemical detection Plasma levels in schizophrenic patients treated with oral or intramuscular depot haloperidol

✍ Manickam Aravagiri; Stephen R. Marder; Theodore Van Putten; Barringer D. Marshal 📂 Article 📅 1994 🏛 Elsevier Science ⚖ 738 KB